Aequus Pharmaceuticals (CVE:AQS) Reaches New 1-Year Low at $0.02

Aequus Pharmaceuticals Inc. (CVE:AQSGet Free Report) shares reached a new 52-week low on Thursday . The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 102000 shares traded. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Price Performance

The stock has a market cap of C$1.99 million, a price-to-earnings ratio of -0.75 and a beta of 0.47. The company has a quick ratio of 0.46, a current ratio of 0.12 and a debt-to-equity ratio of 138.88. The stock has a fifty day moving average of C$0.02 and a two-hundred day moving average of C$0.03.

Aequus Pharmaceuticals (CVE:AQSGet Free Report) last issued its earnings results on Wednesday, November 29th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.01 million during the quarter. As a group, analysts predict that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.

About Aequus Pharmaceuticals

(Get Free Report)

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.

Featured Articles

Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.